152 related articles for article (PubMed ID: 34865221)
1. The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population-based study in the Netherlands, 1989-2018.
Maas CCHM; van Klaveren D; Ector GICG; Posthuma EFM; Visser O; Westerweel PE; Janssen JJWM; Blijlevens NMA; Dinmohamed AG
Br J Haematol; 2022 Mar; 196(5):1219-1224. PubMed ID: 34865221
[TBL] [Abstract][Full Text] [Related]
2. Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population.
Bower H; Björkholm M; Dickman PW; Höglund M; Lambert PC; Andersson TM
J Clin Oncol; 2016 Aug; 34(24):2851-7. PubMed ID: 27325849
[TBL] [Abstract][Full Text] [Related]
3. Chronic myeloid leukemia in the Netherlands: a population-based study on incidence, treatment, and survival in 3585 patients from 1989 to 2012.
Thielen N; Visser O; Ossenkoppele G; Janssen J
Eur J Haematol; 2016 Aug; 97(2):145-54. PubMed ID: 26519944
[TBL] [Abstract][Full Text] [Related]
4. The rising prevalence of chronic myeloid leukemia in France.
Delord M; Foulon S; Cayuela JM; Rousselot P; Bonastre J
Leuk Res; 2018 Jun; 69():94-99. PubMed ID: 29734071
[TBL] [Abstract][Full Text] [Related]
5. Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study.
Shih YT; Cortes JE; Kantarjian HM
Lancet Haematol; 2019 Aug; 6(8):e398-e408. PubMed ID: 31208943
[TBL] [Abstract][Full Text] [Related]
6. Health-related quality of life using EQ-5D among chronic myeloid leukaemia patients in health centres in Klang Valley, Malaysia.
Wan Puteh SE; Aizuddin AN; Tumian NR; Sathar J; Mohamad Selamat E
PLoS One; 2021; 16(8):e0256804. PubMed ID: 34449814
[TBL] [Abstract][Full Text] [Related]
7. A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years.
Lang AS; Mounier M; Roques M; Chretien ML; Boulin M
J Clin Pharm Ther; 2015 Aug; 40(4):391-7. PubMed ID: 25865674
[TBL] [Abstract][Full Text] [Related]
8. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
[TBL] [Abstract][Full Text] [Related]
9. Conditional relative survival among adult patients with chronic myeloid leukemia in the tyrosine kinase inhibitor era: a population-based study in the Netherlands.
Ector GICG; Visser O; Posthuma EFM; Westerweel PE; Janssen JJWM; Blijlevens NMA; Dinmohamed AG
Leukemia; 2021 Nov; 35(11):3291-3294. PubMed ID: 33603145
[No Abstract] [Full Text] [Related]
10. Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era.
Gunnarsson N; Stenke L; Höglund M; Sandin F; Björkholm M; Dreimane A; Lambe M; Markevärn B; Olsson-Strömberg U; Richter J; Wadenvik H; Wallvik J; Själander A
Br J Haematol; 2015 Jun; 169(5):683-8. PubMed ID: 25817799
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
[TBL] [Abstract][Full Text] [Related]
12. CML Chapter.
Snyder D
Cancer Treat Res; 2021; 181():97-114. PubMed ID: 34626357
[TBL] [Abstract][Full Text] [Related]
13. Chronic myeloid leukemia incidence, survival and accessibility of tyrosine kinase inhibitors: a report from population-based Lithuanian haematological disease registry 2000-2013.
Beinortas T; Tavorienė I; Žvirblis T; Gerbutavičius R; Jurgutis M; Griškevičius L
BMC Cancer; 2016 Mar; 16():198. PubMed ID: 26956037
[TBL] [Abstract][Full Text] [Related]
14. Incidence of Second Malignancies of Chronic Myeloid Leukemia During Treatment With Tyrosine Kinase Inhibitors.
Yin XF; Wang JH; Li X; Yu MX; Ma ZX; Jin J
Clin Lymphoma Myeloma Leuk; 2016 Oct; 16(10):577-581. PubMed ID: 27397576
[TBL] [Abstract][Full Text] [Related]
15. The impact of new generic formulations of imatinib mesylate on general quality of life in chronic phase chronic myeloid leukaemia patients.
Uyanik MS; Pamuk GE; Maden M; Merev E; Cevik G; Uyanik V; Umit EG; Demir AM; Akker M
Eur J Cancer Care (Engl); 2017 Mar; 26(2):. PubMed ID: 26594025
[TBL] [Abstract][Full Text] [Related]
16. The costs of treating and not treating patients with chronic myeloid leukemia with tyrosine kinase inhibitors among Medicare patients in the United States.
Seymour EK; Ruterbusch JJ; Winn AN; George JA; Beebe-Dimmer JL; Schiffer CA
Cancer; 2021 Jan; 127(1):93-102. PubMed ID: 33119175
[TBL] [Abstract][Full Text] [Related]
17. Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors.
Sasaki K; Kantarjian HM; Jain P; Jabbour EJ; Ravandi F; Konopleva M; Borthakur G; Takahashi K; Pemmaraju N; Daver N; Pierce SA; O'Brien SM; Cortes JE
Cancer; 2016 Jan; 122(2):238-48. PubMed ID: 26479889
[TBL] [Abstract][Full Text] [Related]
18. Incidence and outcome of BCR-ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors.
Etienne G; Dulucq S; Huguet F; Schmitt A; Lascaux A; Hayette S; Fort MP; Sujobert P; Bijou F; Morisset S; Tavitian S; Bidet A; Turcq B; Robbesyn F; Chollet C; Belloc F; Durrieu F; Mahon FX; Nicolini FE
Cancer Med; 2019 Sep; 8(11):5173-5182. PubMed ID: 31350815
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Imatinib Treatment in Elderly Patients With Chronic Myeloid Leukemia: Real-Life Data and a Single-Center Experience.
Eşkazan AE; Özmen D; Öztaş M; Bektaş F; Bayraktar EA; Sadri S; Keskin D; Özgür Yurttaş N; Elverdi T; Salihoğlu A; Ar MC; Öngören Ş; Başlar Z; Aydın Y; Soysal T
Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):549-557. PubMed ID: 34052176
[TBL] [Abstract][Full Text] [Related]
20. Survival trends in childhood chronic myeloid leukaemia in Southern-Eastern Europe and the United States of America.
Karalexi MA; Baka M; Ryzhov A; Zborovskaya A; Dimitrova N; Zivkovic S; Eser S; Antunes L; Sekerija M; Zagar T; Bastos J; Demetriou A; Agius D; Florea M; Coza D; Polychronopoulou S; Stiakaki E; Moschovi M; Hatzipantelis E; Kourti M; Graphakos S; Pombo-de-Oliveira MS; Adami HO; Petridou ET
Eur J Cancer; 2016 Nov; 67():183-190. PubMed ID: 27677054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
